@article {2337, title = {Antigout Activity of Terap (Artocarpus odoratissimus Blanco) Leaves Extract: Leaves Characteristic and In Vitro Studies}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {August 2024}, pages = {764-769}, type = {Original Article}, chapter = {764}, abstract = {

Terap leaves (Artocarpus odoratissimus Blanco) contain various chemical constituents, making it a herbal medicine prospective source, particularly as an antigout. This research aim to determinate characteristics of terap leaves and in vitro antigout activity of terap leaves ethanolic extract. The determination leaves characteristics included macroscopic and microscopic analysis, water and ethanol soluble extract content, and drying shrinkage. The extract antigout activity was determinated through inhibition of xanthine oxidase enzyme in vitro. Leaves characteristics analysis revealed that mature leaves are approximately 31.5 cm long and 18 cm wide. Terap leaves are single leaves, elliptical, blunt leaf tips, rounded bases, rough surfaces, undulating edges, pinnate veins, and yellow veins. Microscopic analysis reveals the presence of anomocytic-type stomata, trichomes, glandular hairs, resin ducts, and trachea. Terap leaves have a water-soluble extract content of 8.72\%, ethanol-soluble extract content of 4.29\%, and drying shrinkage of 11.38\%. The antigout activity tests results indicates that ethanol extract inhibits xanthine oxidase enzyme with an IC50 of 89.63 μg/mL. Terap leaves have antigout properties, so they have the potential to be developed into a quality antigout herbal medicine.

}, keywords = {Antigout Activity, Artocarpus odoratissimus, Macroscopic and Microscopic Analysis., Xanthine Oxidase Enzyme}, doi = {10.5530/pj.2024.16.127}, author = {Nisa Naspiah and Retno Widyowati and Sukardiman} } @article {2444, title = {Cytotoxic Potential of Mitragyna speciosa as Anticancer - A Review}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {December 2024}, pages = {1418-1423}, type = {Review Article}, chapter = {1418}, abstract = {

Background: Herbal treatment has been proposed and researched as an alternative to cancer treatment. One of the reasons contains compounds that have cytotoxic effects. Mitragyna speciosa are known to contain alkaloids and have a cytotoxic effect. Objective: This review aimed to provide information about preclinical studies and investigates the cytotoxicity or anticancer activity of M. speciosa. Methods: Search articles through PubMed, Springer, and Science Direct databases focusing on preclinical trials according to PRISMA guidelines. A database search yielded a total of 206 identifiable studies. Then duplicate removal and feasibility screening were carried out, resulting in 11 studies that were eligible for final analysis. Results: The anticancer potentials reviewed in this study include Neuroblastoma, Leukemia, Colon Cancer, Breast Cancer, Kidney \& Liver Cytotoxicity, Glutathione Transferases Metabolizing Enzymes, Alkaloid Combination of M. speciosa \& Cisplatin, Alkaloid Combination of M. speciosa \& Doxorubicin and Mutagenic-Antimutagenic Activity of M. speciosa. Extracts and dominant alkaloids of M. speciosa have the potential for anticancer neuroblastoma, leukemia, colon, lung and breast cancer. Based on the safety aspect of the mitragynine compound, there is no mutagenic effect on cells. Conclusion: M. speciosa contains the dominant active alkaloid compound, mitragynine. Extracts and alkaloids dominant in M. speciosa have the potential as an anticancer.

}, keywords = {Alkaloids, Cancer, Cytotoxicity, M. speciosa, Mitragynine}, doi = {10.5530/pj.2024.16.228}, author = {Puja Adi Priatna and Retno Widyowati and Sukardiman} } @article {2073, title = {Phytochemical Compounds Identification From 70\% Ethanol Extract of Arcangelesia Flava (L.) Merr Stems Using LC-MS/MS and In-Silico Molecular Docking Approach as Inhibitor Interleukin-1β}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {August 2023}, pages = {528-534}, type = {Research Article}, chapter = {528}, abstract = {

Arcangelisia flava (L.) Merr has been traditionally used to treat jaundice, liver disease, diarrhea, fever, and inflammation. Judging from its potential, scientific evidence of this plant extract as an inhibitor of interleukin-1β is still lacking. This study aims to investigate the phytochemical compounds present in the 70\% ethanol extract of Arcangelesia flava stems by LC-MS/MS and to elucidate the ligand-protein interactions through in-silico studies. The extract was found to contain alkaloids, flavonoids, furanoditerpene, hydroxyquinoline, phenylpropanoid, phenol, and fatty acids. According to molecular docking of the 15 compounds analyzed by LC-MS/MS, the compounds 3-hydroxy-3{\textquoteright},4{\textquoteright},5{\textquoteright}-trimethoxyflavone (ΔG=-7.72 kcal/mol), fisisaine (ΔG=-6,91 kcal/mol), and demethyleneberberine (ΔG=-6.85 kcal/mol), which demonstrated the highest affinity for binding to the protein target. In addition, active amino acids contribute to this interaction by creating strong hydrogen bonds, such as MET148, LYS 103, and THR300. Phytochemical compounds from Arcangelesia flava may serve as adjunctive therapy or a promising source of advanced structures in drug discovery for treatments targeting interleukin-1β

}, keywords = {Arcangelisia flava (L.) Merr, Inhibitor interleukin-1β, LC-MS/MS, Molecular Docking.}, doi = {10.5530/pj.2023.15.114}, author = {Rizki Rahmadi Pratama and Irawati Sholikhah and Sukardiman and Ram Kumar Sahu and Retno Widyowati} } @article {1929, title = {Molecular Docking Estrogen Receptor Alpha Antagonist and P53- MDM2 Inhibitor, ADMET Prediction of Alkaloid Compound from Mitragyna speciosa for Breast Cancer Therapy}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {January 2023}, pages = {912-916}, type = {Original Article }, chapter = {912}, abstract = {

Introduction: Breast cancer is one of the major universal health problems affecting more than two million cases per year. Estrogen receptor alpha (ERα) and P53 are common targets for the treatment of breast cancer and are primarily involved in cell proliferation. The function of p53 protein is regulated by direct binding to MDM2 protein. Therefore, inhibition of p53-MDM2 interaction leads to reactivating p53 activity. Alkaloid compounds generally have potential anticancer effect. Alkaloid compound from Mitragyna speciosa have the potential for anticancer. Methods: The method used is molecular docking with AutoDockTools 1.5.6 program. Predict the properties of physicochemical, pharmacokinetic, and toxicity prediction tests (ADMET) using pkCSM. Results: The results showed that speciophylline, corynoxine A, and corynoxine B have the best values in free binding energy (ΔG) for estrogen receptor (ERα) alpha receptor. Meanwhile, mitraphylline, mitrafoline, and corynoxine B have the best values for protein P53. Predict ADMET using the pkCSM, the alkaloid compound has strong lipophilicity and good permeability so it predicts the ability to penetrate intestinal cell membranes and the skin membrane. Spesiofilin, mitraphylline, and mitrafolin are not expected hepatotoxic. Conclusion: Speciophylline and mitraphylline have potential as anticancer drugs through the inhibitory of estrogen receptor alpha and MDM2 reseptor.

}, keywords = {ADMET, Alkaloid, Breast cancer, Docking, Mitragyna speciosa}, doi = {10.5530/pj.2022.14.188}, author = {Puja Adi Priatna and Rizki Rahmadi Pratama and Retno Widyowati and Sukardiman} }